Lampalizumab
- Generic Name
- Lampalizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1278466-20-8
- Unique Ingredient Identifier
- UWU93Y99R3
- Background
Lampalizumab has been used in trials studying the treatment of Geographic Atrophy.
- Associated Conditions
- -
- Associated Therapies
- -
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 994
- Registration Number
- NCT02745119
- Locations
- ๐บ๐ธ
Retina Group of Florida, Fort Lauderdale, Florida, United States
๐บ๐ธMaine Eye Center, Portland, Maine, United States
๐บ๐ธVitreo-Retinal Associates, PC, Worcester, Massachusetts, United States
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT02288559
- Locations
- ๐บ๐ธ
Retinal Diagnostic Center, Campbell, California, United States
๐บ๐ธThe Retina Partners, Encino, California, United States
๐บ๐ธLoma Linda University, Loma Linda, California, United States
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 975
- Registration Number
- NCT02247531
- Locations
- ๐บ๐ธ
Southern Vitreoretinal Assoc, Tallahassee, Florida, United States
๐บ๐ธRetina Health Center, Fort Myers, Florida, United States
๐บ๐ธRetina Consultants of Orange County, Fullerton, California, United States
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 906
- Registration Number
- NCT02247479
- Locations
- ๐บ๐ธ
Texas Retina Associates, Arlington, Texas, United States
๐บ๐ธOrange County Retina Med Group, Santa Ana, California, United States
๐บ๐ธMaine Eye Center, Portland, Maine, United States
An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT01602120
- Locations
- ๐บ๐ธ
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
๐ฉ๐ชSt. Franziskus Hospital, Munster, Germany
๐ฉ๐ชUniversitatsklinikum Leipzig, Leipzig, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.